Literature DB >> 1355317

Identification of canine T-lymphocyte subsets with monoclonal antibodies.

D H Gebhard1, P B Carter.   

Abstract

A panel of five murine monoclonal antibodies to canine T-lymphocytes were produced. Antibodies 4.78, 12.125 and 8.358 reacted with approximately 18%, 39% and 60% peripheral blood lymphocytes, respectively. Two color flow cytometric analysis showed that lymphocytes expressing 1.140, 4.78, 8.53 and 12.125 were subsets of lymphocytes expressing 8.358. The lymphocytes expressing 8.358 were negative for surface immunoglobulin. The subsets defined by 1.140, 4.78 or 8.53, 12.125 were mutually exclusive and together account for most cells expressing 8.358 in the peripheral blood, spleen, and lymph node. In the thymus, approximately 47% cells were positive for both 1.140/4.78 and 8.53/12.125. SDS-PAGE analysis of radiolabelled thymus cell lysates demonstrated that antibodies 1.140 and 4.78 immunoprecipitated a 32,35 kd heterodimer under reducing conditions and 12.125 immunoprecipitated a single 56 kd chain under reducing and non-reducing conditions. Antibodies 8.53/12.125 and 1.140/4.78 react with canine lymphocyte populations that occur in proportions similar to lymphocytes expressing CD4 and CD8 like molecules in several primate and non-primate species. The molecules recognized by 12.125 and 1.140/4.78 were similar in size and subunit composition to human CD4 and CD8.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1355317     DOI: 10.1016/0165-2427(92)90181-o

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  7 in total

1.  Compensation for decreased expression of B7 molecules on Leishmania infantum-infected canine macrophages results in restoration of parasite-specific T-cell proliferation and gamma interferon production.

Authors:  E Pinelli; V P Rutten; M Bruysters; P F Moore; E J Ruitenberg
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

2.  Chemokine receptor 7 (CCR7)-expression and IFNγ production define vaccine-specific canine T-cell subsets.

Authors:  Ashley N Hartley; Rick L Tarleton
Journal:  Vet Immunol Immunopathol       Date:  2015-02-07       Impact factor: 2.046

3.  Ex vivo γ-retroviral gene therapy of dogs with X-linked severe combined immunodeficiency and the development of a thymic T cell lymphoma.

Authors:  Douglas R Kennedy; Brian J Hartnett; Jeffrey S Kennedy; William Vernau; Peter F Moore; Thomas O'Malley; Linda C Burkly; Paula S Henthorn; Peter J Felsburg
Journal:  Vet Immunol Immunopathol       Date:  2011-04-14       Impact factor: 2.046

4.  Modulation of cellular and humoral immunity, and disease manifestation during onset of patency in Brugia pahangi-infected dogs.

Authors:  D Schreuer; B Hammerberg
Journal:  Immunology       Date:  1993-08       Impact factor: 7.397

5.  Clinical and immunological effects of human recombinant interleukin-2 given by repetitive weekly infusion to normal dogs.

Authors:  S C Helfand; S A Soergel; P S MacWilliams; J A Hank; P M Sondel
Journal:  Cancer Immunol Immunother       Date:  1994-08       Impact factor: 6.968

6.  Canine parvovirus vaccine elicits protection from the inflammatory and clinical consequences of the disease.

Authors:  T D Yule; M B Roth; K Dreier; A F Johnson; M Palmer-Densmore; K Simmons; R Fanton
Journal:  Vaccine       Date:  1997 Apr-May       Impact factor: 3.641

7.  Vaccination of racing greyhounds: effects on humoral and cellular immunity.

Authors:  G L McMillen; D J Briggs; D S McVey; R M Phillips; F R Jordan
Journal:  Vet Immunol Immunopathol       Date:  1995-11       Impact factor: 2.046

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.